ArticleFrontiers in endocrinology2026
Burden and trends of chronic kidney disease due to type 2 diabetes mellitus in China and G20 countries, 1990-2023: a comparative analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Using the 2023 Global Burden of Disease (GBD) database, we systematically compared the burden of chronic kidney disease due to type 2 diabetes mellitus (T2DM-CKD) between China and G20 countries from 1990 to 2023, and projected trends in the disease burden over the next 26 years. Methods: We used the Joinpoint model to analyze trends in the disease burden over time, applied the Das Gupta decomposition method, and utilized the concentration index and the slope inequality index to assess health inequalities. Finally, we employed ARIMA (Auto Regressive Integrated Moving Average) and BAPC (Bayesian Age-Period-Cohort) models to forecast trends for the period 2024-2050. Results: Over the past 33 years, China's age-standardized incidence, death, and DALY rates (ASIR, ASDR, ASDALYR) all showed a downward trend, with the average annual percentage change (AAPC) of -0.72%, -2.02%, and -1.45%, but aging has driven a steady rise in the absolute burden. The burden of ASIR is concentrated in low Socio-demographic Index (SDI) countries (Concentration Index (CI): -0.168 to -0.277), while the burden of ASDR is shifting toward high-SDI countries (CI: -0.312 to -0.161). The BAPC model projected a 23.2% increase in age-standardized incidence to 2050 (the ARIMA model yielded an unrealistic over-estimation and is not emphasized). Conclusion: China must prepare for a future with a growing population living with chronic conditions and focus on reducing incidence rates among the elderly. Meanwhile, G20 countries require tailored interventions and joint efforts to reduce health inequalities across SDI levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.